source
- BrainChild Bio secures $119M Series A to advance CAR-T therapy for deadly pediatric brain tumorBrainChild Bio announced a $119 million Series A financing round aimed at moving its CAR‑T programs for central nervous system cancers in children forward. The company’s lead candidate, BCB-276, w…
- Novartis' del-desiran fails primary endpoint in phase 3 Harbor trial for myotonic dystrophy type 1Novartis announced that its experimental therapy del-desiran did not meet the primary endpoint in the phase 3 Harbor trial, which evaluated improvement in video hand opening time in patients with m…